Development and validation of a high-throughput zwitterionic hydrophilic interaction liquid chromatography solid-phase extraction-liquid chromatography-tandem mass spectrometry method for determination of the anti-influenza drug peramivir in plasma.

[1]  A. Deelder,et al.  Hydrophilic interaction chromatography-based high-throughput sample preparation method for N-glycan analysis from total human plasma glycoproteins. , 2008, Analytical chemistry.

[2]  N. Day,et al.  Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  Vinod P. Shah,et al.  Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays , 2007, The AAPS Journal.

[4]  James L. Little,et al.  Liquid chromatography-mass spectrometry/mass spectrometry method development for drug metabolism studies: Examining lipid matrix ionization effects in plasma. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  C. Macken,et al.  Neuraminidase Inhibitor Susceptibility Network Position Statement: Antiviral Resistance in Influenza A/H5N1 Viruses , 2005, Antiviral therapy.

[6]  F. Hayden,et al.  Efficacy and Tolerability of the Oral Neuraminidase Inhibitor Peramivir in Experimental Human Influenza: Randomized, Controlled Trials for Prophylaxis and Treatment , 2005, Antiviral therapy.

[7]  J. Gebler,et al.  A rapid sample preparation method for mass spectrometric characterization of N-linked glycans. , 2005, Rapid communications in mass spectrometry : RCM.

[8]  N. Day,et al.  Development and Validation of a Solid-Phase Extraction-Liquid Chromatographic Method for Determination of Amoxicillin in Plasma , 2005, Therapeutic drug monitoring.

[9]  Pooran Chand,et al.  Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo. , 2005, Bioorganic & medicinal chemistry.

[10]  Fabio Garofolo,et al.  Bioanalytical Method Validation , 2004 .

[11]  S. Liao,et al.  Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers , 2002, AAPS PharmSci.

[12]  J. King,et al.  New sample preparation technique for the determination of avoparcin in pressurized hot water extracts from kidney samples. , 2002, Journal of chromatography. A.

[13]  R. Webster,et al.  Comparison of Efficacies of RWJ-270201, Zanamivir, and Oseltamivir against H5N1, H9N2, and Other Avian Influenza Viruses , 2001, Antimicrobial Agents and Chemotherapy.

[14]  D. Smee,et al.  Pharmacodynamic Evaluation of RWJ-270201, a Novel Neuraminidase Inhibitor, in a Lethal Murine Model of Influenza Predicts Efficacy for Once-Daily Dosing , 2001, Antimicrobial Agents and Chemotherapy.

[15]  D. Smee,et al.  In Vivo Influenza Virus-Inhibitory Effects of the Cyclopentane Neuraminidase Inhibitor RWJ-270201 , 2001, Antimicrobial Agents and Chemotherapy.

[16]  S. Bantia,et al.  Anti-influenza virus activity of peramivir in mice with single intramuscular injection. , 2006, Antiviral research.